Severe extrapyramidal symptoms due to valproate plus low dose olanzapine: A case report;Valproata ek olarak düşük doz olanzapin kullanimina baǧli şiddetli ekstrapiramidal bulgular: Bir olgu

Klinik Psikofarmakoloji Bulteni

Volumn 16, Issue 1, 2006, Pages 42-46

  Danki, Demet ^a   Dilbaz, Nesrin ^a   Okay, Ihsan Tuncer ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Behavioral disturbance; Drug interactions; Extrapyramidal system; Mental retardation; Olanzapine; Valproate

Indexed keywords

BIPERIDEN; CLOZAPINE; OLANZAPINE; PROPRANOLOL; RISPERIDONE; VALPROIC ACID;

ADOLESCENT; AKATHISIA; ANAMNESIS; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MENTAL DEFICIENCY; RISK FACTOR; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

EID: 33645535676     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Seeman P, Bzowej NH, Guan HC, Bergeron C, Becke LE, Reynolds GP, Bird EO, Riederer P, Jellinger K, Watanabes et al. Human Brain dopamine receptors in children and aging adults. Synapse 1987;1:399-404
2. Stahl SM, Taneli B, Taneli Y, çev. editörleri. Temel Psikofarmakoloji Yelkovan yayincilik, 2000:416
3. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58 (Suppl 10):55-62
4. Bymaster FP, Calligro DO, Falcone JF,Marsh RD, Moore NA, Tyne NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapin. Neuropsychopharmocology 1996;14:87-96
5. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14 (Suppl 2):S111-123
6. Evren CE. Olanzapin: Yeni atipik antipsikotik. Klinik Psikofarmakoloji Bülteni 1998;8:74-80
7. Bymaster FP, Calligaro DO, Falcone JF, Marsh AD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96
8. Stockton ME, Rasmussen K. Electrophyiological effects of olanzapine, a novel antipsychotic, an A9 and A10 dopamine neurons. Neuropsychopharmacology 1996;14:97-104
9. Casey DE. Tardive dyskinesia,in Psychopharmacology: The Third Generation of progress.Editd by Meltzer HY. New York, Raven Press, 1987:1411-1419
10. Nyberg S, Farde L, Halldin CA PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healty subjects. Neuropsychopharmacology 1997;16:17
11. Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, Ell PO, Nohria V, Kerwin RW. Dopamine D2 receptor occupancy in vivo by the novel antipsychotic olanzapine:a 123I IBZM single photon emission tomography (SPECT) study. Psychopharmacology 1996;124:148-153
12. Sacristan JA, Gomez JC, Ferre F, Gascon J, Perez Bravo A, Olivares JM. Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study. Actas Esp Psiquiatr 2001;29:25-32
13. Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y , Gal G, Kikinzon L, Tyano S, Weizman R, Ratzoni G. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 2003;110:545-560
14. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Clin Psychiatry 2003;64:898-906
15. Baldwin DS, Montgomery SA. First clinical experience with olanzapin (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol 1995;10:239-244
16. Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988;145:869-871
17. Lewander T, Westerberg SE, Ogren SO, Von Bahr C, Kohler C. Remoxipride, a selective antagonist of dopamine D2 receptors, in the treatment of delusional psychoses. Encephale 1990;16:153-157
18. Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol Ser 1988;5:74-93
19. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983;40:1113-1117
20. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesher GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58 (Suppl 5):S205-211
21. Lu LM, Lane HY. Olanzapine-induced tardive dyskinesia. BMJ 2003;182:81-82
22. Conley RR, Meltzer HY. Adverse events related to olanzapine. J Clin Psychiatry 2000;61 (Suppl 8):26-29
23. Dunayevich E, Strakowski SM. Olanzapine-induced tardive dystonia Am J Psychiatry 1999;156:(Suppl 10):1662
24. Robertson J, Emerson E, Gregory N, Hatton C, Kessissoglu S, Hallam A. Receipt of psychotropic medication by people with intellectual disability in residental settings. J Intellect Disabil Res 2000;44:666-676
25. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning:a double blind ,placebo-controlled pilot trial. J Child Adol Psychopharmacol 2001;11:5-13
26. Cueta MJ, Peralta V, Zarzuella A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia:a longtidunal study. Sch Res 2001;48:17-28
27. Advokat CD, Mayville EA, Matson JL. Side effect profiles of atypical antipsychotics,or no psychotropic medications in persons with mental retardation. Res Dev Disabil 2000;21:75-84
28. Woods SW, Martin A, Spector SG, McGlashan TH. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc. Psychiatry 2002;41:1439-1446
29. Bozabali ÖG, Baykara B, Baykara A. Çocuk ve ergenlerde 5 farkli psikiyatrik bozuklukta olanzapin kullanimi. Klinik Psikofarmakoloji Bülteni 2002;12:179-183
30. Beasley CM Jr; Tollefson GD; Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58 ( Suppl 10):S13-17